<DOC>
	<DOCNO>NCT00871195</DOCNO>
	<brief_summary>The objective study evaluate performance Sequenom 's noninvasive test fetal RHD genotype . The test use MALDI-TOF mass spectrometry detect DNA . The study specifically design determine whether RHD type use free fetal DNA maternal circulation accurately predict neonatal RhD phenotype birth .</brief_summary>
	<brief_title>A Noninvasive Test Fetal RHD Genotype</brief_title>
	<detailed_description>In United States Canada , routine obstetrical care include blood test determine blood type mother ( ABO RhD ) . An antibody screen anti-red cell antibodies mother 's serum also perform . Postpartum prophylactic treatment RhD negative woman anti-D immunoglobulin prevent `` RhD Disease '' , hemolytic disease fetus/newborn , initiated 1960 's . In mid 1980 's , routine administration antenatal anti-D immunoglobulin become standard care well . Although treatment dramatically reduce incidence RhD Disease , approximately 40 % RhD negative pregnancy continue receive unnecessary injection antenatal anti-D immunoglobulin . Genotyping platform MALDI-TOF mass spectrometry allow precise sensitive detection fetal-specific ( paternally derive ) alleles maternal plasma . In study , Sequenom 's MassARRAY technology use assess noninvasive test fetal RHD genotyping clinical setting .</detailed_description>
	<criteria>Female least 18 year age RhD negative serology Pregnant 1113 week gestation confirm ultrasound Willing provide sign date informed consent Able willing comply protocol RhD negative woman know alloimmunized RhD antigen</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2012</verification_date>
	<keyword>Rhesus D</keyword>
	<keyword>RHD</keyword>
	<keyword>genotype</keyword>
	<keyword>phenotype</keyword>
	<keyword>neonatal</keyword>
	<keyword>noninvasive</keyword>
	<keyword>fetal</keyword>
	<keyword>MassARRAY</keyword>
	<keyword>DNA</keyword>
</DOC>